Evaluation of oxaliplatin and tigio combination therapy in locally advanced gastric cancer

doi:10.4240/wjgs.v16.i6.1709

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 6

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3486)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

173

HTML

1285

Figures (1-2)

548

Tables (1-3)

406

Sum=2412

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

110

Download

786

Sum=896

Jun 27, 2024 (publication date) through Feb 17, 2026

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Surg. Jun 27, 2024; 16(6): 1709-1716
Published online Jun 27, 2024. doi: 10.4240/wjgs.v16.i6.1709

Evaluation of oxaliplatin and tigio combination therapy in locally advanced gastric cancer

Teng Wang, Li-Yun Zhang

Teng Wang, Li-Yun Zhang, Department of Gastroenterology, Xianyang Hospital, Yan’an University, Xianyang 712000, Shaanxi Province, China

Author contributions: Zhang LY designed this study, collected and analyzed the data; Wang T drafted the manuscript and gave final approval of the version to be published; Wang T and Zhang LY took part in this study as endoscopic operators or assistants.

Institutional review board statement: The study was reviewed and approved by the Medical Ethics Committee of Xianyang Hospital, Yan’an University (Approval No. 2023-299).

Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

Conflict-of-interest statement: The authors declare that there is no competing interest associated with the manuscript.

Data sharing statement: No additional data are available.

Corresponding author: Li-Yun Zhang, MM, Associate Chief Physician, Department of Gastroenterology, Xianyang Hospital, Yan’an University, Wenjin New Town Residential Area, Yingbin Avenue, Weicheng District, Xianyang 712000, Shaanxi Province, China. zhangliyun0301111@163.com

Received: March 5, 2024
Revised: April 26, 2024
Accepted: May 14, 2024
Published online: June 27, 2024
Processing time: 116 Days and 22.4 Hours

Abstract

BACKGROUND

Locally advanced gastric cancer (LAGC) is a common malignant tumor. In recent years, neoadjuvant chemotherapy has gradually become popular for the treatment of LAGC.

AIM

To investigate the efficacy of oxaliplatin combined with a tigio neoadjuvant chemotherapy regimen vs a conventional chemotherapy regimen for LAGC.

METHODS

Ninety patients with LAGC were selected and randomly divided into control and study groups with 45 patients in each group, according to the numerical table method. The control group was treated with conventional chemotherapy, and the study group was treated with oxaliplatin combined with tigio-neoadjuvant chemotherapy. The primary outcome measures were the clinical objective response rate (ORR) and surgical resection rate (SRR), whereas the secondary outcome measures were safety and Karnofsky Performance Status score.

RESULTS

The ORR in the study group was 80.00%, which was significantly higher than that of the control group (57.78%). In the study group, SRR was 75.56%, which was significantly higher than that of the control group (57.78%). There were 15.56% adverse reactions in the study group and 35.56% in the control group. These differences were statistically significant between the two groups.

CONCLUSION

The combination of oxaliplatin and tigio before surgery as neoadjuvant chemotherapy for patients with LAGC can effectively improve the ORR and SRR and is safe.

Keywords: Locally advanced gastric cancer; Oxaliplatin and tigio; Neoadjuvant chemotherapy; Surgical resection rate; Objective response rate; Clinical efficacy

Core Tip: This study identified the following highlights. The objective response rate in the study was 80.00%, which was significantly higher than that of the control group (57.78%). In the study group, 75.56% of the tumors were resected, which was significantly higher than that of the control group (57.78%). There were 15.56% adverse reactions in the study group and 35.56% in the control group. These differences were statistically significant between the two groups.